Heidelberg, Germany
Heidelberg, Germany

Time filter

Source Type

Grant
Agency: European Commission | Branch: FP7 | Program: BSG-SME | Phase: SME-1 | Award Amount: 1.47M | Year: 2011

Regenerative Medicine (use of cells and tissue to replace or heal impaired functions in the body, RM) is one of the fastest growing areas in todays medicine, and has the potential to offer treatment to patients with diseases that are currently untreatable. In many new areas of RM there is however a need to improve the outcome of RM concepts and technologies for it to become a viable option to traditional medicine, or even to motivate the risk of clinical trials and treatments. One of the main problems in several RM areas is that a large portion of the cell and tissue material is lost or made dysfunctional during and shortly after transplantation and that the transplant does not connect to the host tissue as a functional new graft. The specific scientific objective of this project is twofold: 1) to clinically test and prove that Corline Heparin Surfaces (CHS) can be used to protect donated human insulin producing cells that are transplanted to severe cases of Diabetes Type 1 patients, and 2) to broaden the application of the technology and show that the CHS technology can function as a protective and revascularization promoting technology for other Regenerative Medicine areas. The goal is to show CHSs further applicability to Liver Cell therapy, Xeno transplantation of Islet of Langerhans and to Tissue Engineering In addition to the detailed scientific objective, this project has a specific technological objective. The technological objective of this project is to, in partnerships with the participating SMEs, improve European top grade clinical Regenerative Medicine products by combining them with the CHS technology, transferring the application knowledge and integrating the CHS technology into the partners cell and tissue production processes, and to set up a reliable sourcing chain with supply and production of reagents and tissue products to end-user.


Rattay K.,German Cancer Research Center | Claude J.,German Cancer Research Center | Rezavandy E.,German Cancer Research Center | Matt S.,German Cancer Research Center | And 4 more authors.
Journal of Immunology | Year: 2015

Promiscuous expression of a plethora of tissue-restricted Ags (TRAs) by medullary thymic epithelial cells (mTECs) plays an essential role in T cell tolerance. Although the cellular mechanisms by which promiscuous gene expression (pGE) imposes T cell tolerance have been well characterized, the underlying molecular mechanisms remain poorly understood. The autoimmune regulator (AIRE) is to date the only validated molecule known to regulate pGE. AIRE is part of higher-order multiprotein complexes, which promote transcription, elongation, and splicing of a wide range of target genes. How AIRE and its partners mediate these various effects at the molecular level is still largely unclear. Using a yeast two-hybrid screen, we searched for novel AIRE-interacting proteins and identified the homeodomain-interacting protein kinase 2 (HIPK2) as a novel partner. HIPK2 partially colocalized with AIRE in nuclear bodies upon cotransfection and in human mTECs in situ. Moreover, HIPK2 phosphorylated AIRE in vitro and suppressed the coactivator activity of AIRE in a kinase-dependent manner. To evaluate the role of Hipk2 in modulating the function of AIRE in vivo, we compared whole-genome gene signatures of purified mTEC subsets from TEC-specific Hipk2 knockout mice with control mice and identified a small set of differentially expressed genes. Unexpectedly, most differentially expressed genes were confined to the CD80lo mTEC subset and preferentially included AIRE-independent TRAs. Thus, although it modulates gene expression in mTECs and in addition affects the size of the medullary compartment, TEC-specific HIPK2 deletion only mildly affects AIRE-directed pGE in vivo. Copyright © 2015 by The American Association of Immunologists, Inc.


The invention relates to a process for the preparation of disinfected single-cell preparations from mammalian tissues and to the preparations thus prepared.


Patent
Cytonet GmbH | Date: 2011-07-30

A method for isolating urea and removing CO_(2 )from plasma samples, comprising the following steps: a) providing a plasma sample; b) adding an acid so as to partially remove CO_(2); c) lyophilizing the sample so as to further remove CO_(2 )and obtain a dried sample; and d) redissolving the dried sample and neutralizing to a pH value of 4 to 7 using a buffer solution, wherein optionally a filtration step is carried out before adding the acid.


Patent
Cytonet GmbH | Date: 2013-09-16

Microcapsules including a capsule shell encapsulating a suspension of a therapeutically effective amount of liver cells in physical contact with a liver cell stimulating amount of erythropoietin.


Trademark
Cytonet GmbH | Date: 2010-07-06

pharmaceutical preparations, in particular pharmaceuticals made from human adult hepatocytes for the treatment of liver disease and metabolic disorder; veterinary preparations, in particular pharmaceuticals of human adult hepatocytes for the treatment of liver disease and metabolic disorder in cattle, in particular horses, cows, bulls, sheep and pets, in particular dogs, cats, birds and wild animals, in particular elephants, lions, camels, zebras. scientific and technological services and research activities, in particular the testing of hepatic tissue and pharmaceuticals; industrial analysis and research services, in particular the technical analysis of hepatic tissue and pharmaceuticals; advice in the field of medical and pharmaceutical research relating to the scientific examination and analysis of hepatocytes. Medical and veterinary services; healthcare for humans and animals, in particular therapy for humans or animals using hepatocytes; medical and pharmaceutical consultation, namely, medical and pharmaceutical advice in relation to medical analysis of hepatocytes and in relation to pharmaceuticals.


Trademark
Cytonet GmbH | Date: 2012-04-24

Pharmaceutical preparations, in particular pharmaceuticals made from human adult hepatocytes for the treatment of liver disease and metabolic disorder; all of the foregoing goods excluding gastro-enterological preparations and anti-ulcer preparations. Scientific and technological services and research activities, in particular the testing of hepatic tissue and pharmaceuticals, excluding gastro-enterological preparations and anti-ulcer preparations; industrial analysis and research services, in particular the technical analysis of hepatic tissue and pharmaceuticals, excluding gastro-enterological preparations and anti-ulcer preparations; advice in the field of medical and pharmaceutical research relating to the scientific examination and analysis of hepatocytes; scientific research and scientific services in the nature of investigations for medical purposes in the field of cell therapy. Medical and veterinary services; healthcare for humans and animals, in particular therapy for humans or animals using hepatocytes; medical and pharmaceutical consultation, namely, medical and pharmaceutical advice in relation to medical analysis of hepatocytes and in relation to pharmaceuticals, excluding gastro-enterological preparations and anti-ulcer preparations.


Trademark
Cytonet GmbH | Date: 2012-08-24

Pharmaceutical and veterinary preparations, in particular pharmaceuticals of human adult hepatocytes for the treatment of heavy to life-threatening liver and cellular diseases as well as for metabolism diseases of the liver; all pharmaceutical preparations not for distribution in pharmacies and not as over-the-counter-drugs. Scientific and technological services and research activities, in particular the examination of hepatic tissue and pharmaceuticals; industrial analysis and research services, in particular the analysis of hepatic tissue and pharmaceuticals. Medical and veterinary services; healthcare for humans and animals, in particular therapy of the human or animal body with hepatocytes; medical advice in the examination and analysis of hepatocytes and in the production of pharmaceuticals.


Trademark
Cytonet GmbH | Date: 2012-05-04

pharmaceutical and veterinary preparations, namely, made from human adult hepatocytes for the treatment of liver and cellular diseases as well as for metabolism diseases of the liver. Scientific and technological services and research activities, namely, the examination of hepatic tissue and pharmaceuticals; industrial analysis and research services, namely, the analysis of hepatic tissue and pharmaceuticals. Medical and veterinary services; healthcare services for humans and animals, namely, therapy for humans or animals using hepatocytes; medical counseling in relation to medical examination and analysis of hepatocytes and in relation to the production of pharmaceuticals.


Trademark
Cytonet GmbH | Date: 2015-04-21

Pharmaceutical preparations, in particular cell preparations excluding preparations for the treatment of diseases of the gastro-intestinal apparatus (stomach and bowel) as well as anti-ulcer medicines. Scientific and technological services and research activities, in particular the testing of hepatic tissue and pharmaceuticals; industrial analysis and research services, in particular the technical analysis of hepatic tissue and pharmaceuticals; advice in the field of medical and pharmaceutical research relating to the scientific examination and analysis of hepatocytes; scientific research and scientific services, in particular investigations for medical purposes in the field of cell therapy and cell analysis; services in the field of the development of cell preparations. Medical and veterinary services; healthcare for humans and animals, in particular therapy for humans or animals using hepatocytes; medical and pharmaceutical consultation, in particular medical and pharmaceutical advice in relation to medical analysis of hepatocytes and in relation to pharmaceuticals.

Loading Cytonet GmbH collaborators
Loading Cytonet GmbH collaborators